PRINCETON, N.J.— October 13, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in … Continued
PRINCETON, N.J.— August 31, 2022 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Morgan Stanley 20th Annual Global Healthcare ConferenceDate and Time: Tuesday, September 13 at 11:45 a.m. ET Baird Global Healthcare ConferenceDate and Time: Wednesday, September 14 at 12:15 p.m. … Continued
Biosimulation software and services fuel second quarter growth PRINCETON, N.J.—August 9, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance. Second Quarter Highlights: Revenue was $82.8 million, compared to $70.1 million in the second quarter … Continued
New automation, analytics and collaboration features save time and ensure regulatory compliance PRINCETON, N.J., August 5 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release 5.2.0 of Pinnacle 21 Enterprise, the Company’s flagship software for validating clinical trial data for biosimulation and regulatory submissions. It also introduced the new … Continued
Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies PRINCETON, N.J.— July 28, 2022 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a 2-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop new biosimulation software. Certara will be working with the MSK Innovation … Continued
PRINCETON, N.J., July 25, 2022 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company’s board of directors to eleven members. “We are excited to welcome an accomplished business leader with a proven track … Continued
PRINCETON, N.J., July 13, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022. His appointment brings the company’s board of directors to ten members. “Eran has a proven track record taking high-growth healthcare businesses to the next … Continued
PRINCETON, N.J.— July 12, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 after the market close on Tuesday, August 9th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in … Continued
Advances lead optimization, first-in-human dose prediction and formulation development Princeton, N.J., June 28, 2022: Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research. Derived from the industry-leading Simcyp Simulator, Simcyp Discovery increases confidence … Continued
New capabilities enhance clinical predictability for different compounds across more therapeutic areas Princeton, N.J., June 21, 2022: Certara, a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG), Immuno-oncology (IO) and Vaccine Simulators to help predict how drugs work and address key questions in the development of novel biologic … Continued
